Anticoagulant therapy n 124 CADISS P rimary outcome Ipsilateral stroke or allcause mortality for antiplatelet vs anticoagulation 2 vs 1 p 063 Any stroke 2 vs 1 ID: 932756
Download Presentation The PPT/PDF document "Antiplatelet therapy (n = 126)" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Antiplatelet therapy(n = 126)
Anticoagulant therapy(n = 124)
CADISS
Primary outcome: Ipsilateral stroke or all-cause mortality for antiplatelet vs. anticoagulation: 2% vs. 1%; p = 0.63Any stroke: 2% vs. 1%, p = 0.63; any stroke, death, or major bleed: 3% vs. 2%, p = 1.0Major bleeding: 0% vs. 1%
Trial design: Patients with extracranial carotid and vertebral artery dissection were randomized in a 1:1 fashion to receive either antiplatelet therapy or anticoagulation with warfarin with an INR goal of 2-3. They were followed for 3 months.
Results
Conclusions
CADISS Trial Investigators. Lancet Neurol 2015;14:361-7
Primary outcome
Among patients with extracranial carotid or vertebral dissection, recurrent strokes at 3 months are rare, with no difference between antiplatelet and anticoagulant therapyOne of the first head-to-head trials for this rare condition
%
(
p = 0.63)